Avenda Health, an AI healthcare company dedicated to transforming personalized prostate cancer care, has introduced its FDA cleared platform, Unfold AI™. Unfold AI is now being used for the first time in a commercial setting with patients at a renowned U.S. research hospital. By combining deep-learning algorithms with patient-specific data from prostate imaging, biopsies, and pathology, the platform creates a tailored cancer estimation map.
The 3D, AI-generated map visualizes the cancer location, allowing physicians to make better treatment decisions and improve interventional planning. In clinical studies, urologists utilizing Unfold AI have improved their sensitivity of identifying the extent of the tumor to over 98%. The technology aims to revolutionize the way prostate cancer is treated, preserving the quality of life and improving outcomes for patients.
During clinical trials, the platform’s guidance led to changes in treatment recommendations in 28% of cases, often resulting in more localized treatment. Multiple treatment options can be chosen based on Unfold AI’s results, including active surveillance, whole gland treatments like radical prostatectomy and radiation therapy, or soft tissue laser ablation using Avenda Health’s FocalPoint device.
Physicians at the research hospital, including Wayne Brisbane, MD, have adopted the technology in their practice. Avenda Health is committed to making this cutting-edge technology available to all physicians treating prostate cancer patients, ultimately creating a new standard of cancer care.
Unfold AI received 510(k) clearance from the U.S. FDA in December 2022. For more information on Avenda Health and its groundbreaking technology, visit avendahealth.com.